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In 2007, theALK tyrosine kinasewas described as a potential therapeutic target for a subset
of non-small-cell lung cancer patients. Clinical proof of concept, culminating in the recent
approval by the Food and DrugAdministration of the Pﬁzer drug crizotinib followed in record
time.The drugwas approved togetherwith a companion diagnostic for detection of patients
eligible for therapy.This remarkable example of the coming of age of personalized medicine
in cancer therapy is hopefully only an auspice of things to come in a rapidly developing ﬁeld.
Perhaps unsurprisingly, however, the appearance of clinical acquired resistance to crizotinib
was observed early on in clinical testing, with the identiﬁcation of several ALK secondary
point mutations which diminish drug efﬁcacy and which open the way for development of
second-generation inhibitors. It is also emerging that acquired resistance to crizotinib may
additionally occur through ALK-independent mechanisms, which still need to be elucidated
in detail. Here we discuss the factors that led to such a rapid approval of a targeted agent,
and we describe the second-generation compounds currently in development.
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INTRODUCTION
The ALK (anaplastic lymphoma kinase) gene encodes a tyrosine
kinase belonging to the insulin receptor superfamily. ALK is abun-
dantly expressed in neural tissue during embryogenesis, but levels
fall during early development, so that in adults it is expressed
only in rare scattered neural cells (Iwahara et al., 1997; Mor-
ris et al., 1997; Webb et al., 2009; Ardini et al., 2010). ALK was
originally identiﬁed in anaplastic large cell lymphoma (ALCL)
cells as the product of a recurring chromosomal translocation,
t (2;5; p23;q35), between the ALK gene on chromosome 2 and
the nucleophosmin (NPM) gene on chromosome 5, which gives
rise to expression of the NPM–ALK fusion protein (Morris et al.,
1994). The oncogenic potential of NPM–ALK, which contains
a constitutively activated ALK kinase domain, was subsequently
demonstrated in several different preclinical models, conﬁrming
its role in the pathogenesis of ALCL (Shiota et al., 1994; Drexler
et al., 2000). In addition to ALCL,ALK gene translocations or acti-
vating point mutations were identiﬁed in other rare tumor types,
including inﬂammatory myoﬁbroblastic tumors (IMT) and neu-
roblastoma (Webb et al., 2009; Ardini et al., 2010). IMT is a rare
tumor of mesenchymal origin that affects young individuals, with
approximately 50% of cases bearing a chromosomal translocation
involving the ALK gene, fused to many different N-terminal part-
ners (Grifﬁn et al., 1999), while neuroblastoma is a rare pediatric
solid tumor and originates from neural cell-derived tissue, giving
tumor masses localized mainly at the level of the adrenal glands
(Maris et al., 2007). In neuroblastoma, ALK gene ampliﬁcation
and point mutations are found as recurring events, rather than
gene translocation.
Notwithstanding the substantial evidence linking activated
ALK kinase to tumorigenesis in these rare tumors, it is fair to
say that the considerable current enthusiasm for ALK as target for
cancer therapy is largely driven by the relatively recent ﬁnding of a
recurring ALK gene translocation in a signiﬁcant subset (ca. 5%)
of non-small-cell lung cancer (NSCLC, Rikova et al., 2007; Soda
et al., 2007). In ALK-positive NSCLC, ALK gene rearrangement
most often involves an inversion within the short arm of chro-
mosome 2 (between loci 2p21 and 2p23), leading to expression
of echinoderm microtubule associated protein like 4 (EML4)–
ALK, an oncogenic fusion protein composed of the N-terminal
portion of EML4 and the entire intracellular portion of ALK. As
with NPM–ALK, there is much convincing preclinical evidence in
support of the oncogenic nature of EML4–ALK, the requirement
for ALK kinase activity in maintenance of EML4–ALK-dependent
tumor cell growth and of the capacity of selective small mole-
cule kinase inhibitors of ALK to induce cell death in such tumors
(Christensen et al., 2007; Galkin et al., 2007; Choi et al., 2008;
Koivunen et al., 2008; McDermott et al., 2008; Soda et al., 2008).
Subsequent studies of tissue samples from NSCLC patients aimed
at further characterizingALK-positiveNSCLChave led to the iden-
tiﬁcation of a relatively well deﬁned potential patient population,
characterized by speciﬁc clinical–pathological features. It appears
that ALK-positive patients tend to be younger than the median
age for lung cancer patients and are, in general, never-smokers,
or former light smokers, while at the histological level, ALK-
positive tumors are almost exclusively adenocarcinomas, with a
clear component of the signet-ring cell type (Inamura et al., 2008;
Shaw et al., 2009; Solomon et al., 2009; Kwak et al., 2010). The
presence of EML4–ALK rearrangement appears to be mutually
exclusive with KRAS and EGFR mutations, further supporting a
role for ALK as a unique driver of malignancy in these patients,
though interestingly, an exception is possibly represented by the
recent description of a small fraction of crizotinib-naïve patients
reported to possess both EML4–ALK rearrangement and EGFR
mutations (Sasaki et al., 2011), as will be further commented
below.
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CLINICAL VALIDATION OF ALK AS A THERAPEUTIC TARGET
IN ALK-POSITIVE NSCLC
Crizotinib is an orally available drug that was originally discovered
and optimized as an inhibitor of c-Met kinase (Christensen et al.,
2007; Zou et al., 2007). Prior to designation of the International
Non-proprietary Name of “crizotinib” the drug was known as PF-
02341066 (the Pﬁzer company’s chemical collection number for
the compound) and it is now also known as Xalkori®, a Pﬁzer
brand name, but we will subsequently only refer to it in this text as
crizotinib. Studies with c-Met kinase revealed that crizotinib has
a classical ATP-competitive mechanism of action and as is often
the case for such inhibitors, it was subsequently found to cross-
react with a few “off-target” kinases. In particular, potent activity
of the drug on ALK was revealed through selectivity proﬁling in
biochemical assay and ALK-driven cellular models (Christensen
et al., 2007). A multi-indication Phase I clinical trial of crizotinib
in solid tumors and lymphomas had already been initiated, with
the drug described as a“c-Met/Hepatocyte Growth Factor tyrosine
kinase inhibitor” (ClinicalTrials.gov Identiﬁer: NCT00585195),
when identiﬁcation of the genetic rearrangement involving ALK
in NSCLC was ﬁrst reported (Soda et al., 2007). In 2008, while
preclinical data supporting a therapeutic rationale for targeting
ALK in NSCLC was still emerging, ALK-positive patients started
to be enrolled in this already ongoing Phase I trial. ALK cross-
reactivity of crizotinib, apparently initially seen as a possible path
for registration of the compound in niche indications such as
chemotherapy resistant ALCL, now became a major opportunity.
Thus, patient screening and enrollment of ALK-positive subjects
into the trial was initiated,using amethodology based on the break
apart probe FISH (ﬂuorescent in situ hybridization) technique,
with a kit speciﬁcally developed for detecting ALK transloca-
tion in patient tumor samples (Perner et al., 2008). Within a
few months, impressive preliminary data on clinical response in
these patients became available. A dedicated Phase I/II clinical
trial focused on ALK-positive NSCLC patients was completed in
2010 (Kwak et al., 2010), barely 3 years after the ﬁrst description of
this genetic lesion. After the standard dose escalation Phase I that
deﬁned the recommended dose of 250mg twice a day per 28-day
cycle, an expanded cohort of ALK-positiveNSCLCwas selected for
treatment. Approximately 1500 NSCLC patients were screened by
FISH, identifying 82 patients considered eligible and then enrolled
in the expanded cohort study. Most of these patients had received
previous therapy and almost half were heavily pre-treated. The
overall objective response rate in this study was 57% (47 out of
82 patients, with 46 conﬁrmed partial response and 1 complete
response), with a further 33% of patients (27 out of 82) in stable
disease. The estimated probability of 6-month progression-free
survival was 72%. To date, the median overall survival time from
initiation of crizotinib has not been determined, but 1-year overall
survival was 74% and 2-year overall survival was 54% (Kwak et al.,
2010; Shaw et al., 2011).
The spectacular efﬁcacy observed for crizotinib in this chal-
lenging setting was associated with relatively mild side effects.
The most frequently reported were gastrointestinal toxicities,
with grade 1 nausea and diarrhea and visual disturbances, but
with no abnormalities detected in ophthalmological examination.
Increased levels of hepatic transaminases were also observed, but
only reaching grade 3 in a limited number of patients (5 and 6%
for ALT and AST, respectively). Two randomized Phase III clinical
trials in ALK-positive NSCLC are currently underway to compare
the activity of crizotinib to standard of care.Nevertheless, based on
the impressive responses observed in Phase I/II trial, the Food and
Drug Administration (FDA) approved crizotinib for treatment of
ALK rearranged NSCLC, under its accelerated approval program,
onAugust 26, 2011. The National Comprehensive Cancer network
guidelines recommend the use of crizotinib as ﬁrst line therapy for
ALK-positive selected NSCLC patients (www.nccn.org).
Other patients affected by rare malignancies for which a clear
involvement of ALK had been demonstrated in preclinical stud-
ies, were also enrolled in the trial with crizotinib. For at least
two patients with ALK-positive ALCL treated at the recom-
mended Phase II dose, signs of clinical beneﬁt were seen within a
remarkably short treatment period, with a PR and a CR achieved
(Gambacorti-Passerini and Messa, 2011). Two patients with IMT
were enrolled already in the dose escalation phase: for one of
these, a rapid and sustained partial response was seen. The other
patient had no response to crizotinib, but retrospective genetic
analysis showed that this IMT tumor lacked ALK rearrangement
(Butrynski et al., 2010).
CURRENT TREATMENT OF ALK-POSITIVE TUMORS:
SUCCESSES AND CHALLENGES
Current publicly available data indicate that crizotinib therapy
of ALK-positive NSCLC patients is associated with a median
progression-free survival time of circa 10months. However, soon
after publication of efﬁcacy results of Phase I/II trials, early data on
relapse to crizotinib due to newly acquired secondarymutations in
theALKkinase domainwere also reported (Choi et al., 2010; Sasaki
et al., 2010). This observation poignantly reﬂects previous clinical
experience with other inhibitors that selectively target kinases to
which“oncogene addiction”appears to be adriving force for tumor
growth. A wealth of clinical data has been accumulated, for exam-
ple, with the EGFR inhibitors geﬁtinib and erlotinib in NSCLC
patients bearing EGFR mutations, with imatinib and sunitinib in
c-Kit dependent GIST tumors and with imatinib in Bcr–Abl posi-
tive CML patients. It has been amply demonstrated that relapse to
these agents is often linked to acquired resistance to the inhibitor
due to secondary mutations in the target kinase domain which
compromise drug inhibitory activity (Shah et al., 2002; Tamborini
et al., 2004; Carter et al., 2005; Kobayashi et al., 2005). In fact, that
crizotinibmight also be susceptible to such a resistancemechanism
hadbeen suggested by preclinical studieswith kinase domainpoint
mutants of ALK corresponding to those found in neuroblastoma.
Several different single amino acid mutations of ALK are known in
this disease, all mapping to the cytoplasmic portion of the receptor
and most of which induce constitutive kinase activity of the full
length receptor (Chen et al., 2008; George et al., 2008; Janoueix-
Lerosey et al., 2008; Mossé et al., 2008). Intriguingly, biochemical
and cellular studies revealed that not all neuroblastoma mutants
are equally susceptible to inhibition by ATP-competitive kinase
inhibitors, including crizotinib. For example, crizotinib maintains
activity against the R1275Q mutant, but drastically loses activity
against F1174L, another frequently occurring mutant (Wood et al.,
2009; Sakamoto et al., 2011; Schönherr et al., 2011). These ﬁndings
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indicate that the ALK kinase domain can naturally undergo single
point mutations which result in loss of sensitivity to crizotinib
compared with the wild-type domain.
Perhaps unsurprisingly, therefore, DNA sequence analyses per-
formed in three relapsed NSCLC patients and in the IMT case
which, after successful treatment with crizotinib for a few months,
had acquired resistance to therapy, have identiﬁed four differ-
ent de novo secondary mutations that are compellingly linked to
acquired drug resistance. The L1196M gatekeeper mutation and
the C1156Y and L1152R mutants were identiﬁed in the relapsed
NSCLC cases, and the F1174L mutation in the relapsed IMT (Choi
et al., 2010; Sasaki et al., 2010, 2011). The mechanisms underlying
decreased activity of crizotinib on these secondary ALK mutants
were investigated by structural and biochemical analyses, together
with cellular data generated in engineered in vitro models. For
the L1196M, C1156Y, and L1152R mutants, it appears that bind-
ing of the inhibitor to ALK may be negatively affected by steric
hindrance or conformational changes in the enzyme. F1174L,
which recapitulates the primarymutation found in neuroblastoma
previously shown to render the enzyme insensitive to crizotinib,
appears instead to induce a conformational change in the pro-
tein which results in increased afﬁnity for ATP itself. This latter
type of resistance mechanism is highly reminiscent of that pre-
viously described for resistance of EGFR to geﬁtinib (Iressa) and
erlotinib (Tarceva) in NSCLC patients as a result of the T790M
secondary mutation in EGFR (Yun et al., 2008) and by analogy,
all ALK inhibitors with an ATP-competitive binding mechanism
may be destined to display decreased inhibitory activity when
the F1174L mutation appears. Consequently, effective targeting
of this mutant may require extremely high afﬁnity or irreversible
inhibitors.
Thus, after the initial wave of enthusiasm to crizotinib in
the scientiﬁc and NSCLC patient communities, the need for
second-generation ALK inhibitors became quickly evident.
However, another key ﬁnding emerging from the clinical data
available to date is that not all cases of acquired resistance to crizo-
tinib are necessarily due to secondary mutations in ALK itself,
since in some relapsed NSCLC lesions, no secondary ALK muta-
tion is detectable (Sasaki et al., 2010). Mechanisms underlying
ALK-independent resistance have not yet been extensively elu-
cidated, but it is likely that in some patients relapse is due to
activation of alternative signal transduction pathways, so that the
tumor is no longer solely critically dependent upon ALK signal-
ing. The only ﬁrm data available to date in this regard are derived
from a single NSCLC case in which increased levels of EGFR sig-
naling were detected after acquired resistance to crizotinib and a
limited genetic study in treatment-naïve ALK rearranged NSCLC
cases suggests that EGFR mutations may be present in circa 5%
of such cases (Sasaki et al., 2011). In this context, it is interesting
to note that in addition to secondary mutation of EGFR, c-Met
ampliﬁcation has been associated with acquired resistance to the
EGFR inhibitors geﬁtinib and erlotinib in NSCLC patients bearing
activating mutations of EGFR (Engelman et al., 2007). A similar
scenario is seen in B-raf mutated melanoma patients in relapse
from therapy with the B-raf inhibitor vemurafenib, in which pro-
gression does not appear, at least to date, to be associated with
acquisitionof secondarymutations inB-rafV600E,but ratherwith
induction of alternative pathways for MAPK activation, including
Cot, PDGFR, and MEK1 dependent signaling (Johannessen et al.,
2010; Nazarian et al., 2010).
We can thus envisage that in future, specimens from relapsed
patients will be subjected to detailed molecular analyses aimed at
verifying ﬁrstly whether secondary ALK mutation is present and
then whether other resistance phenomena such as EGFR mutation
or c-Met ampliﬁcation have by-passedALK signaling (see Figure 1
for a schematic view of crizotinib mode of action in ALK-positive
NSCLC and the two currently postulatedmechanisms for acquired
resistance).
This would in theory open a perspective of combination of
crizotinib with other targeted therapies for treatment of a subset
of ALK-positive patients with acquired resistance. For example, in
the case of acquired ALK inhibitor resistance due to collateral EGF
receptor activation, such an approach would be immediately fea-
sible by combination of crizotinib with already approved agents
such as geﬁtinib and erlotinib. In the case of c-Met ampliﬁcation
as a potential crizotinib resistance mechanism in NSCLC, as has
been amply described for the EGFR inhibitors, it will be extremely
interesting to see whether or not this occurs, given that crizotinib
cross-reacts strongly with c-Met and that emerging clinical evi-
dence indicates that the drug has activity in a c-Met-ampliﬁed
context (Lennerz et al., 2011).
NEW DRUGS TARGETING ALK
To date, crizotinib remains the only drug that has been evaluated
in clinical trials beyond Phase I. However, several new ALK kinase
inhibitors have been described, with some already in early clini-
cal development (Table 1). Clinical development strategies for the
most advanced molecules appear to be based on two approaches: a
ﬁrst“all-comer”approach including both crizotinib-naïve patients
and patients who developed acquired crizotinib resistance after
initial response and a second focusing solely on patients with
acquired resistance (Hallberg and Palmer, 2011; Sasaki and Jänne,
2011).
CH5424802 (Chugai Pharmaceutical, a subsidiary of Roche)
is a potent, selective, and orally available kinase inhibitor of
ALK. It is an ATP-competitive inhibitor and displays strong
anti-proliferative activity in different ALK–driven tumor models
in vitro, as well as in vivo, with impressive anti-tumor activity
in ALK-positive NSCLC, ALCL, and neuroblastoma xenografts
(Sakamoto et al., 2011). Preclinical characterization of the drug
included evaluationof thepotencyof CH5424802onALKmutants
using both biochemical enzyme assays and engineered cellular
models. Good biochemical potency was reported on L1196M,
C1156Y, and F1174L mutated proteins, with low nanomolar IC50
or K i values, comparable to that found on wild-type ALK. In vitro
studies performed on Ba/F3 cells expressing mutated ALK kinase
forms supported the biochemical data, conﬁrming potent inhibi-
tion of L1196M and C1156Y mutants in a cellular setting. In vivo
efﬁcacy was described only for the L1196M gatekeeper mutation,
conﬁrming a higher potency with respect to crizotinib in inhibit-
ing the in vivo growth of ALK–L1196M driven Ba/F3 cells. For
the F1174L mutant, activity in Ba/F3 cells was not described, but
the compound was able to effectively inhibit proliferation of a
neuroblastoma cell line naturally bearing the mutation.
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FIGURE 1 | Echinoderm microtubule associated protein like 4–ALK is a
driver oncogene in ca. 5% of NSCLC, engaging multiple downstream
signaling pathways, including the MAPK andAKT pathways (upper
panel). Crizotinib inactivates EML4–ALK kinase activity, disengaging
oncogenic signaling pathways, thus inducing growth arrest and cell death
(middle panel). Upon sustained selective pressure following ALK inhibition by
crizotinib, tumors can acquire resistance through two types of mechanism:
ALK-dependent (lower left panel) or ALK-independent (lower right panel). In
ALK-dependent acquired resistance, ALK can undergo secondary mutations
which abrogate ability of crizotinib to inhibit its kinase activity (some known
clinically relevant mutations are indicated). For this type of resistance
second-generation ALK inhibitors might be particularly effective. In
ALK-independent acquired resistance, activation of alternative signaling
pathways (e.g., EGFR, c-MET, or downstream signaling components) occurs
collateral to ALK activation, removing the absolute requirement for ALK as a
driver oncogene. In this case, it can be hypothesized that ALK is still present
and inhibited by drug, so that combination therapy with an ALK inhibitor
would be a therapeutic option.
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Table 1 | ALK small molecule inhibitors.
Compound Company Declared specificity Phase/clinical trial
PF-2341066 Crizotinib Xalkori® Pﬁzer MET/ALK Approved for ALK+ late stage NSCLC
CH5424802 Chugai Pharmaceuticals ALK I/II JapicCTI-101264
LDK378 Novartis ALK I NCT01283516
AP26113 Ariad Pharmaceuticals ALK/EGFR I/II NCT01449461
ASP3026 Astellas Pharma ALK I NCT01284192, NCT01401504
X-396 Xcovery ALK Preclinical
GSK-1838705 GlaxoSmithKline ALK/IGF-1R Preclinical
NMS-E628 Nerviano Medical Sciences ALK/TRK Preclinical
CH5424802 is currently under clinical evaluation in an open-
labeled Phase I/II trial in NSCLC patients in Japan (ClinicalTri-
als.gov Identiﬁer: Japic CTI-101264). The trial is scheduled to be
completed in March 2014.
LDK378 (Novartis) is an orally available ALK inhibitor that
is being evaluated in an open-label dose escalation Phase I
trial in ALK rearranged tumors (ClinicalTrials.gov Identiﬁer:
NCT01283516). Three different arms are foreseen, includingALK-
positive crizotinib-naïve NSCLC patients, ALK-positive NSCLC
patients previously treated with other ALK inhibitors and all
ALK-positive tumors other than NSCLC, respectively. Limited
information on preclinical evaluation are publicly available for
this drug. LDK378 appears very efﬁcacious in vivo, inducing com-
plete and durable tumor regression in an ALK-positive NSCLC
dependent model and was also described to be active in tumors
bearing the C1156Y mutation that confers crizotinib resistance (Li
et al., 2011).
AP26113 (Ariad Pharmaceuticals) is a potent and orally avail-
able inhibitor of ALK whose chemical structure has not been
disclosed. Biochemical characterization shows that in addition
to ALK, the compound cross-reacts with a number of other
kinases (>45 inhibited with IC50< 200 nM), among which EGFR
is inhibited with an IC50 of 129 nM. Considering that EGFR
is a well validated target per se in NSCLC and that in at least
one case, resistance to crizotinib was associated with EGFR acti-
vation, this cross-reactivity was considered an opportunity by
the company and the compound is in clinical testing as a dual
ALK/EGFR inhibitor. Additionally, AP26113 was evaluated on the
crizotinib resistant gatekeeper mutant L1196M both in vitro and
in vivo and appeared to be able to overcome resistance to crizo-
tinib. K i determination demonstrated a very similar biochemical
potency on wild-typeALK and the L1196MALK mutant (0.09 and
0.08 nM respectively), with both cellular and in vivo data (using
engineered Ba/F3 cells) indicating that growth of ALK–L1196M
mutant driven-cells is inhibited at similar, albeit slightly higher,
doses which inhibit cells harboring wild-type ALK (Katayama
et al., 2011). AP26113 was also described to be active on a series
of in vitro induced crizotinib resistant mutations, which how-
ever have not been observed to date in clinical cases of acquired
crizotinib resistance (Zhang et al., 2010).
Clinical development of this drug has initiated recently (Sep-
tember 2011), with a Two-Stage development strategy (Clinical-
Trials.gov Identiﬁer: NCT01449461). The initial dose escalation
will be conducted in patients with advanced cancers, particularly
NSCLC. The expanded cohort of patients treated at the RP2D
will include four genetically deﬁned patient populations: includ-
ing: patients with ALK-positive NSCLC who have not previously
received anALK inhibitor, patients withALK-positiveNSCLCwho
are resistant to at least oneALK inhibitor, patients with EGFR pos-
itive NSCLC who are resistant to at least one prior EGFR inhibitor
and patients with other cancers expressing ALK.
ASP3026 (Astellas) is an orally available ALK inhibitor, for
which no preclinical data are publicly available. The compound
is being evaluated in a phase I, non-randomized, open-label,
study in patients with solid tumors (ClinicalTrials.gov Identi-
ﬁer: NCT01401504). The trial initiated in December 2010 and
is scheduled to be completed in April 2013.
X-296/X-396 (Xcovery) are aminopyridazine-based ALK
kinase inhibitors which display good anti-tumor activity in vitro
and in vivo on different ALK-dependent tumor models. X-396 was
also evaluated onL1196MandC1156Ymutations and data suggest
that it can potentially overcome at least these crizotinib resistance
mutations. Pharmacokinetic properties and toxicity proﬁles are
described as favorable for X-396 and suggest that this might be a
future candidate for clinical testing (Lovly et al., 2011). Addition-
ally,data regarding the distribution of X-396 in brain tissue suggest
that this drug might also possess activity against ALK-positive
brain metastases.
GSK1838705A, a compound originally identiﬁed as potent,
ATP-competitive inhibitor of IGF-1R and insulin receptor, has
been described to be highly active against ALK kinase (Sabba-
tini et al., 2009). In vivo, tumor growth inhibition in ALK-positive
xenograftmodels was observed,withminimal and transient effects
on glucose homeostasis, suggesting that, despite potential dia-
betogenic effects, an acceptable therapeutic window might be
achieved by schedule modulation. No information are available
for this compound regarding activity against crizotinib resistant
ALK mutants.
NMS-E628 (Nerviano Medical Sciences), from the authors’
own group, is an orally available small molecule inhibitor of
ALK kinase activity for which preclinical characterization has been
completed,with the compound approaching clinical development.
NMS-E628 selectively inhibits ALK-dependent cell prolifera-
tion at 100 nM or below and is able to induce tumor regression
in several preclinical ALK-dependent models, with some animals
remaining tumor-free for extended periods of time after the end
of the treatment. Preclinical pharmacokinetic studies show that
NMS-E628 is able to efﬁciently cross the blood–brain barrier.
Efﬁcacy following oral administration in an intracranial growth
model of the H2228 NSCLC xenograft conﬁrmed that efﬁcacious
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exposures can be reached in the brain and support the possible use
of NMS-E628 in patients bearing brain metastases (Ardini et al.,
2009).When tested inBa/F3 cells drivenbyALKmutants identiﬁed
in crizotinib-relapsed patients, NMS-E628 is circa ﬁvefold more
potent than crizotinib in inhibiting the proliferation of L1196M
ALK and C1156Y ALK-driven-cells in vitro and in vivo (Ardini
et al., 2011). Thus, on the basis of increased potency and abil-
ity to cross the blood–brain barrier, NMS-E628 might represent a
valid therapeutic opportunity for crizotinib-relapsed patients that
experience acquired resistance to speciﬁc ALK mutations.
FUTURE PERSPECTIVES
Crizotinib recently received accelerated approval from the FDA,
coming hot on the heels of the B-raf inhibitor vemurafenib (Zelb-
oraf®, approved August 17, 2011 for melanoma patients with the
B-raf V600E mutation). Signiﬁcantly, both agents were approved
not for a broad indication, but for a molecularly deﬁned subset
of patients and both were approved with a companion diagnostic
test. Unlike vemurafenib, crizotinib is an “off-the shelf” inhibitor
in the sense that it was already in clinical development when the
molecular setting for which it was eventually approved was dis-
covered. This certainly gave the compound a strong competitive
advantage over those originating within ALK-focused programs,
but what contributed vitally to its successful registration was the
efﬁciency with which ALK-positive NSCLC patients, which repre-
sent only circa 5% of the indication, were detected and selected
for treatment within the expansion arm of the ﬁrst Phase I/II
studies. Such logistic efﬁciency, organization, and vision on the
part of Pﬁzer and collaborators is praiseworthy and indeed reg-
istration and marketing of the drug were made possible by the
parallel availability of a companion diagnostic test, the Vysis ALK
Break Apart FISH Probe Kit (Abbott Molecular, Inc.) which was
approved alongside crizotinib for detection of patients eligible for
treatment with the drug (FDA News, August 26, 2011).
Data available to date and comparison with other kinase
inhibitors approved for NSCLC, such as geﬁtinib and erlotinib,
indicate that in most cases, treatment of ALK-driven tumors
with crizotinib will not be curative, but that relapse will occur
with at least two types of mechanism, differing on the basis of
whether or not tumors retain ALK-dependency. In the case of
ALK-dependent relapse, current evidence indicates that acquired
resistance to crizotinibwill certainly occur through secondaryALK
mutations, resulting in variants which are intrinsically less sensi-
tive to the drug, but it has also been suggested that crizotinib
may possess other weaknesses, such as inability of the drug to
act effectively in pharmacological “sanctuary” sites, for example
beyond the blood–brain barrier (Camidge, 2011). This is an
important consideration for a disease in which circa 40–50%
of cases experience brain metastases (Eichler et al., 2011). For
ALK-dependent progressive disease, several second-generation
compounds, originating from ALK-focused programs, are cur-
rently undergoing, or will soon enter clinical testing and it is likely
that efﬁcacious new agents will emerge amongst these within the
next couple of years.
With regards to ALK-independent acquired resistance to crizo-
tinib, it is not yet clear how frequently this will occur and which
signaling pathways will be involved. However, we expect that
approaches such as “deep” DNA sequencing of relapsed lesions
(e.g., Ross and Cronin, 2010) and genome-wide functional genetic
studies (e.g., Ashworth and Bernards, 2010) will deﬁne major
resistance mechanisms, some of which, such as EGF receptor acti-
vation, may be suitable for targeting in combination with ALK
inhibition.
From a Pharmaceutical point of view, it is clear that ALK was
relatively neglected as a target for drug discovery until the emer-
gence of its role in NSCLC. Despite the great interest this ﬁnding
has since generated,ALK targeting nonetheless remains a relatively
niche area for drug discovery, given that only ca. 5% of NSCLC
patients harbor the rearrangement and that the other ALK-driven
malignancies known to date are very rare tumor types. Several
factors therefore came into play in the relatively rapid clinical
development of crizotinib and appearance on the scene of second-
generation ALK inhibitors. Firstly, the great deal of emphasis that
both large pharmas and small biotechs have placed on develop-
ing kinase programs in the last two decades means that kinases
are amongst the best characterized enzyme classes from the phar-
macological point of view, with inhibitors now available, on the
benchtop at least, for hundreds of kinases (e.g., Posy et al., 2011).
The ever-increasing understanding of “chemical space” for target-
ing this class of enzyme means that today, identiﬁcation of kinase
inhibitors is a relatively rapid and low-cost process compared to
other classes of drug target.
Another important factor that was key for the successful clinical
development of crizotinib is the rapid deﬁnition of the molecular
characteristics of patients likely to beneﬁt from therapy and the
application of a reliable diagnostic method for upfront identiﬁca-
tion of these patients during clinical trials. The Phase I/II responses
observed in patients with rearranged ALK allowed crizotinib to be
reviewed under the FDA’s accelerated approval program, which
permits conditional approval of a drug for a serious disease based
on reasonable likelihood of clinical beneﬁt. In the ﬁeld of can-
cer, in which patients with the speciﬁc genetic context required
for drug activity may be relatively rare within a given tumor type,
this type of provision considerably facilitates clinical development
of targeted agents in the very well deﬁned molecular contexts for
which they were designed. It is probable that development of next
generation compounds targeting secondarymutations of ALKwill
follow a similar strategy.
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